Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Treatment-resistant Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

In this project, the investigators evaluate an accelerated schedule of repetitive transcranial magnetic stimulation for treatment-resistant depression. The investigators focuse on participants' brain activity and blood markers (Reelin, Apoer2, NMDAR, BDNF, exosomes and so on) to deepen the understanding of the mechanism of accelerated rTMS for treatment-resistant depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Device: active iTBS — Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT. Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
  • Device: sham rTMS — The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Primary Outcomes

  • Change in remission rate of Hamilton Depression Scale (24-items) (HAM-D24) score after treatment. (Baseline, 5-day, 1-month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Contact Information
Study Contact:
Manli Huang, M.D
13957162975
huangmanli@zju.edu.cn
Manli Huang, M.D
13957162975
huangmanli@zju.edu.cn
The First Affiliated Hospital of Zhejiang University
Interventions
  • Device: active iTBS — Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT. Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
  • Device: sham rTMS — The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study Locations (1 sites)
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: 1. The current episode met the DSM-5 diagnostic criteria for major depression in patients with first-episode or relapsed unmedicated depression without psychotic symptoms. 2. 24-item Hamilton Depression Scale (HAMD-24) ≥ 20. 3. Age 18-45 years, regardless of gender. 4. Right-handedness. 5. Han Chinese. 6. Signed a written informed consent, willing to participate in the study and be evaluated. Exclusion Criteria: 1. Co-morbid other mental disorders, including: schizophrenia, mental retardation, substance dependence, etc. 2. Patients with metal objects in the body or with other contraindications to MRI scanning 3. Patients with severe or unstable somatic diseases 4. Women during pregnancy or lactation, and women of childbearing age with positive urine HCG test results during the screening period 5. Other conditions that, in the opinion of the investigator, exist that make participation in this clinical trial inappropriate.
Conditions Suicidal Ideation
Phase NA
Enrollment 2200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The overall goal of this study is to respond to the urgent need for an effective suicide prevention strategy for Black youth by examining the effectiveness of a systems-level strategy to recognize and respond to suicide risk among Black adolescents who present to emergency departments (EDs). The proposed strategy, WeCare, combines combines three components: (1) universal screening using the Computerized Adaptive Screen for Suicidal Youth (CASSY), (2) a brief intervention designed for Black youth with elevated suicide risk in for ED settings, Connections for Safety (CFS), that combines safety planning and strategies to support linkage to outpatient mental health services, and (3) supportive text messages to youth and parent/caregivers for six weeks following the youth's ED visit. Study objectives are (1) to integrate input from multiple stakeholders to inform and facilitate WeCare implementation, and (2) to use a hybrid one effectiveness-implementation design to evaluate its effectiveness.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: WeCare — WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.

Primary Outcomes

  • Mental Health Outpatient Visits (Electronic Medical Record) (Baseline, Months 3 and 6)
  • Columbia-Suicide Severity Rating Scale (Baseline, Months 3 and 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-08
Completion: 2027-04-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 2200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: New York University
Collaborators: University of Michigan
Principal Investigators:
  • Michael A Lindsey, PhD (PRINCIPAL_INVESTIGATOR) - New York University
Contact Information
Study Contact:
Michael A Lindsey, PhD
(212) 998-5959
michael.lindsey@nyu.edu
Jacqueline Holloway, PhD
973-941-2376
jacqueline.holloway@nyu.edu
Nasreen Akbar, MD
718-245-2502
akbarn@nychhc.org
Kings County Hospital
Interventions
  • Behavioral: WeCare — WeCare combines two evidence-based strategies -- universal screening using the Computerized Adaptive Screen for Suicidal Youth and an adapted version of the SAFETY-ACUTE, which incorporates PI Lindsey's extensive work with Black youth, their families, and community stakeholders to develop culturally tailored strategies for addressing treatment barriers.
Study Locations (1 sites)
Kings County Hospital, New York, New York 11203 United States
Eligibility Criteria
Inclusion criteria adolescent and parent/guardians: * Adolescents aged 12-17 years and their parents or guardians, and adolescents 18-19 years who have the option for their parent or guardian to participate * Having a parent/caregiver present in the ED to consent or available to consent remotely (12-17 year olds, only) * Having a cellular phone with text messaging capacity * Adolescent able to speak English, and understand study questions * Parents able to consent in English, Spanish, French or Creole * Meet screening criteria Exclusion criteria adolescent and parent/guardians: * Adolescent is medically unstable * Adolescent present with severe cognitive impairment * Parents are not present in the ED, unable to consent remotely, and not able to give consent in either English, Spanish, French or Creole (12-17 year olds, only) * Adolescent does not have access to cellular phone * Adolescents active in mental health treatment (e.g., seen a therapist, social worker, or mental health provider in the last week)
Conditions Hyperthermia, Major Depressive Disorder,...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to examine how whole-body hyperthermia affects the thermoinflammatory profile, which includes the combined immune and heat shock response, in patients with depression and whether these changes correlate with decreased depression in individuals with Major Depressive Disorder.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Device: WBH — Hyperthermia exposure using Heckel Hyperthermia Device
  • Device: Sham — Sham (mild heating) using Heckel Hyperthermia Device

Primary Outcomes

  • Changes in serum levels of Interleukin-6 from baseline to post-treatment (baseline (pre-intervention), one hour post-intervention, 24 hours post-intervention, one week post-intervention)
  • Decreases in depressive severity, as measured by the Inventory of Depressive Symptomatology, Clinician-Rated (IDS-CR) (baseline (pre-intervention), one week post-intervention, two weeks post-intervention, four weeks post-intervention)
  • Decreases in depressive severity, as measured by the Symptoms of Depression Questionnaire (SDQ) (baseline (pre-intervention), 24 hours post-intervention, one week post-intervention, two weeks post-intervention, four weeks post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-01
Completion: 2024-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Institute of General Medical Sciences (NIGMS)
Contact Information
Study Contact:
Simmie Foster, MD PhD
617-643-7427
sfoster4@partners.org
Maren Nyer, PhD
617-643-4897
mnyer@mgh.harvard.edu
Study Coordinator
617-724-3222
mgh-wbh@partners.org
Massachusetts General Hospital Depression Clinical & Research Program
Interventions
  • Device: WBH — Hyperthermia exposure using Heckel Hyperthermia Device
  • Device: Sham — Sham (mild heating) using Heckel Hyperthermia Device
Study Locations (1 sites)
Massachusetts General Hospital Depression Clinical & Research Program, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Females and Males ages 18-65 2. English language proficiency 3. Ability to provide informed consent 4. Have a current primary psychiatric diagnosis of major depressive disorder (MDD) of at least 4 weeks duration, as defined by Diagnostic \& Statistical Manual, 5th Edition (DSM-5) criteria using the MINI. 5. Score of ≥ 24 on the Inventory of Depressive Symptomatology - Clinician Rated (IDS-CR) 6. Individuals of childbearing potential must use an acceptable form of birth control. Exclusion Criteria: 1. Pregnancy or planned pregnancy during study 2. Current breastfeeding 3. History of psychiatric hospitalization within the past year 4. Active suicidal intent ("yes" on item 4 or 5 on the Columbia-Suicide Severity Rating Scale) 5. History of bipolar disorder, psychotic disorders, eating disorders, and/or substance abuse or dependence (within the last year), as per the Mini-International Neuropsychiatric Interview (MINI) 6. Meeting DSM-5 criteria at screening for current obsessive compulsive disorder 7. A ≥25% drop in IDS-CR score from screen (V1) to baseline (V1b) 8. Positive urine toxicology screen due to illicit drug use or other exclusionary medications. (Potential false positives will be addressed on a case-by-case basis at the discretion of the investigator) 9. Serious unstable medical condition including cardiovascular, neurological, neoplastic, autoimmune, infectious or endocrine. 10. Morbid obesity (BMI \> 40) and/or body shape that might increase the risk of cutaneous burning from the Heckel hyperthermia device (because of truncal skin being too close to the infrared lights). 11. Any history of or current diagnosis of thrombosis or thrombophilia; if it is unclear whether a subject has received this diagnosis, a signed release will be obtained to contact the subject's treating physician and obtain accurate diagnostic information. Depending on the recommendation of the treating physician, the subject may undergo appropriate testing with the treating physician to verify the diagnosis, and if the tests produce negative findings, the subject may be allowed to enter the study 12. Has a history of or an increased risk for gastrointestinal perforation such as a history of diverticulitis, stomach or intestinal ulcers or abdominal pain that does not go away 13. Using medication that might impact thermoregulatory capacity within 3 days of receiving WBH treatment, including: diuretics, barbiturates, beta-blockers, antipsychotic agents, anti-cholinergic agents or chronic use of antihistamines, aspirin (other than low-dose for prophylactic purposes), non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids, or cytokine antagonists. 14. Use of any medication that could interact in such a way as to potentiate the sedative effect of lorazepam or ondansetron, or otherwise deemed unsafe per physician judgment. 15. Fever (Temp \> 99) of unknown origin at the time of screen 16. Breast Implants 17. Unsafe cardiac status as defined by abnormal ECG reading at screening visit as determined by medical monitor, study doctor, or subject's primary care physician or cardiologist 18. Claustrophobia of sufficient severity to interfere with ability to enter/remain in Heckel device 19. A subject who in the opinion of the Principal Investigator would not be able to safely complete the study or would jeopardize study integrity

At-Home tDCS as Maintenance Therapy

NCT07269964
Recruiting
Conditions MDD, Severe Depression, Major Depressive...
Phase NA
Enrollment 30
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The primary purpuse of this pilot study is to find out whether a home-based transcranial direct current stimulation (tDCS) program is feasible and well tolerated as maintenance therapy and whether there are early signs that it helps maintain the clinical clinical benefits achieved during successful acute inpatient treatment. Participant population: Adults (18+) with depressive disorder who had already improved/stabilized after acute treatment at our clinic (esketamine, repetitive transcranial magnetic stimulation , or electroconvulsive therapy). Main questions: Feasibility: Do participants reliably complete the home program and stay in the study? Preliminary effectiveness: Do improvements of depressive symptoms hold up over the 4-week treatment and 2-week follow-up (based on self-report and clinician-rated scales)? Participants receive standardized instruction from trained staff and a portable tDCS device (with cap and small sponge electrodes) and complete 20 home sessions over 4 weeks (5 per week), each 30 minutes at a very low current (2 mA); the device gently ramps current up/down for comfort. During treatment, participants use a smartphone app with step-by-step guidance and reminders; sessions are automatically logged. They will also fill out short weekly self-rating questionnaires and join brief phone check-ins every 2 weeks. Where: Department and Outpatient Clinic of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich Safety \& data privacy: The device monitors electrode contact and pauses automatically if contact is poor. Typical sensations can include mild tingling or redness. The app stores anonymized session data so the care team can track progress; no personal data are exchanged between the app and the stimulator, and access is via a secure clinical portal.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: tDCS — Description: Transcranial Direct Current Stimulation delivered at an intensity of 2 mA over electrodes at F3/F4 (bifrontal, over DLPFC), for 30 minutes a day, Monday to Friday, for a total 20 sessions.

Primary Outcomes

  • Feasibility, number of completed sessions (4 weeks from baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2026-11-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Technical University of Munich
Contact Information
Study Contact:
Ulrike Vogelmann, Dr. med.
+4917661535471
ulrike.vogelmann@mri.tum.de
Ulrike Vogelmann, MD
+498941406882
ulrike.vogelmann@mri.tum.de
Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital
Interventions
  • Device: tDCS — Description: Transcranial Direct Current Stimulation delivered at an intensity of 2 mA over electrodes at F3/F4 (bifrontal, over DLPFC), for 30 minutes a day, Monday to Friday, for a total 20 sessions.
Study Locations (2 sites)
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,, München, Bavaria 81675 Germany
Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital, München, 81675 Germany
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years). * Diagnosis according to ICD-10: recurrent depressive disorder, severe depressive disorder, schizoaffective disorder (depressive episode) or bipolar affective disorder (depressive episode). * Clear indication for maintenance therapy after successful acute treatment (esketamine, rTMS, or ECT) with remission/improvement of symptoms. * Capacity to provide informed consent, confirmed in a physician-led consent discussion. Exclusion Criteria: * Currently in the acute treatment phase of an affective disorder and non-response to previous treatments. * Currently clinically relevant Axis II disorders. * Suicidal risk, including suicidal ideation. * Contraindications for tDCS: e.g., skin disease at electrode sites, cochlear implants. * Neurological, somatic, or psychiatric comorbidities that could compromise validity or safety.
Conditions Depression
Phase NA
Enrollment 960
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Low income women of childbearing age are at increased risk for depression and often do not receive needed treatment. Investigators developed Mom-Net, an on-line cognitive behavioral treatment (CBT) for depression to address the needs of low income women of childbearing age. The intervention program also includes live coaching to help the mothers engage and learn the CBT material. Mom-Net has been shown to be highly effective in reducing depressive symptoms and improving parenting behavior and child adjustment, in earlier controlled trials. In this project the investigators are examining whether access to Mom-Net can be expanded by delivering it in Head Starts (HS). To address that broad question, the investigators will focus on two sets of scientific questions: 1. Implementation Questions: e.g., Can HS agencies deliver the program successfully; do HSs choose to sustain the program after the research project ends; what agency characteristics are associated with successful delivery of Mom-Net); 2. Effectiveness Questions: e.g., Does Mom-Net reduce maternal depression when delivered by Head Start agencies, with HS staff doing the coaching? Head Start agencies will be randomized to deliver either Mom-Net with the usual high-intensity coaching or with a low-intensity coaching alternative. Within each agency, depressed mothers will be randomized to receive either: 1) Mom-Net program; or 2) Treatment as Usual (TAU;) referral to community mental health providers). Mothers initially assigned to the TAU condition, will have the option of receiving Mom-Net at a later date. Mothers will participate in assessments of depressive symptoms, parenting behavior, and child adjustment at Time 1 (T1; prior to randomization); and Time 2 (T2; after the intervention period) and Time 3 (T3; one year after T1).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Mom-Net — Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff. In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later.
  • Behavioral: Treatment as Usual/Waitlist — HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies

Primary Outcomes

  • Patient Health Questionnaire-9 (PHQ-9) (Assessing change between baseline, post-intervention (5 months), and follow up (12 months))
  • Maternal Acceptability (Modified System Usability Scale) (Post intervention ( 5 months))
  • Screening Reach (Reach) (End of screening in year 2 of implementation)
  • Implementation Reach (IReach) (End of Implementation in Year 2)
  • Maternal Engagement (Engage) (Change between base-line and 5-month assessments)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-12-01
Completion: 2027-03-31
Eligibility
Age: 2 Years and older
Sex: ALL
Volunteers: false
Enrollment: 960 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oregon Research Institute
Principal Investigators:
  • Edward G Feil, Ph.D. (PRINCIPAL_INVESTIGATOR) - Oregon Research Institute
Contact Information
Study Contact:
Edward G Feil, Ph.D.
541-484-2123
Edf@ori.org
Kendra E Guinness, Ph.D.
541-484-2123
kguinness@ori.org
Edward G Feil, Ph.D.
541-484-2123
edf@ori.org
Oregon Research Institute
Interventions
  • Behavioral: Mom-Net — Mom-Net is a guided Internet intervention. Mom-Net is distinct from other CBT interventions for depression in addressing the link between maternal depression and parenting. Mom-Net's content includes core CBT skills taught in ways that are relevant to one's parenting interactions. Mothers will participate in Mom-Net with either high- or low-intensity coaching as determined by which version their HS was randomized to offer. Coaching is provided by HS staff. In the high-intensity version, coaches provide support both for engaging with the intervention and for learning content. Coaching phone calls occur weekly (20-30 min call per session). In the low-intensity version, coaches provides supportive accountability for engaging with the intervention. Mothers participate in 4 (10-15) min calls occurring post-randomization, and 3- and 6-weeks later.
  • Behavioral: Treatment as Usual/Waitlist — HS sites provide ongoing social and instrumental support to parents, including helping to connect families to needed services including community mental health providers. Additionally, research staff will provide lists of local mental health providers and information to support treatment seeking. Research staff will also provide National Crisis Lines for Mental Health Emergencies. Staff will inform participants to call research staff if they have trouble accessing services so that staff may provide additional help. Finally, staff will share a case note documenting referrals with the women's family service worker, so that worker may provide locally based assistance to the woman in accessing services. Subsequent to T2 assessment, participants in the TAU/Waitlist condition, will be offered the Mom-Net intervention variant (high- v low-intensity coaching) being provided by their respective HS agencies
Study Locations (1 sites)
Oregon Research Institute, Springfield, Oregon 97477 United States
Eligibility Criteria
Inclusion Criteria: Mothers * Elevated symptoms of depression (i.e., Patient Health Questionnaire or Edinburgh Postnatal Depression Scale score at or above 10) * Have a child 2-5 years enrolled in a participating Head Start; be able to communicate in English or Spanish. Inclusion Criteria: Child \- 2-5 years of age and enrolled in participation Head Start Exclusion Criteria: Mothers * Evidence of psychosis or other major mental illness or cognitive disability (observed during recruitment or by HS report) that would interfere with meaningful participation * Endorsed score of 3 on final item of the PHQ9 or EPDS indicating frequent thoughts of suicide. Could be enrolled at later date if elevated risk ameliorates Exclusion Criteria: Children * No exclusion criteria
Conditions Depression
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

150 patients with moderate to severe depression, recently discharged from a psychiatric ward and now recieving treatment at an outpatient unit at Mental Health Center Copenhagen, will be randomised in to two groups. A treatment ad usual (TAU) group and an Advance-group. The Advance-group will receive a psychotherapeutic intervention focusing on advancing sleep timing to improve depression.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: CRT-Advance — Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
  • Behavioral: Treatment as usual — Treatment as usual in the outpatient psychiatric unit.

Primary Outcomes

  • Beck Depression Inventory II (BDI-II) (at inclusion, at two weeks, at fourweeks, at six weeks, and at endpoint (after eight weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Bispebjerg and Frederiksberg
Principal Investigators:
  • Klaus Martiny, Professor (STUDY_DIRECTOR) - Mental Health Center Copenhagen
Contact Information
Study Contact:
Anne Sofie Kvist Houby, MD
28780878
anne.sofie.kvist.houby@regionh.dk
Klaus Martiny, Professor
klaus.martiny@regionh.dk
Anne Sofie Kvist Houby, MD
28780878
anne.sofie.kvist.houby@regionh.dk
Mental Health Center Copenhagen
Interventions
  • Behavioral: CRT-Advance — Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.
  • Behavioral: Treatment as usual — Treatment as usual in the outpatient psychiatric unit.
Study Locations (1 sites)
Mental Health Center Copenhagen, Copenhagen, Frederiksberg 2000 Denmark
Eligibility Criteria
Inclusion Criteria: * Moderate to major depression (DSM-V) * Discharge from psychiatric ward within last 30 days * Sleep onset and/or sleep off-set delayed minimum 1 hour based on the last three days, comparred to sleep in the last week of admittance at the psychiatric ward. Exclusion Criteria: * Psychotic depression. * Cognitive problems making participation difficult. * Substance abuse (e.g. alcohol). * Increased suicidal risk.
Conditions Anhedonia, Emotional Blunting
Phase PHASE1
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting. The study will test whether a single 25 mg dose of psilocybin, compared with placebo, can improve these symptoms and improve the function of brain circuits involved in reward and motivation. Researchers will measure changes using brain imaging (fMRI) and clinical questionnaires, including the Dimensional Anhedonia Rating Scale (DARS).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Psilocybin — One-time dose of psilocybin 25 mg, oral, in capsule form.
  • Drug: Placebo — One-time dose of placebo (25 mg of inert filler), oral, in capsule form.

Primary Outcomes

  • Change in Dimensional Anhedonia Rating Scale (DARS) Score (Baseline (Week -3), End of Study (Week 8))
  • Change in Fronto-Striatal Connectivity (pgACC-NAcc FC) (Baseline (Week -3), End of Study (Week 8))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-09
Completion: 2030-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Joshua Siegel, MD, PhD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Julia Diamond
646-754-4744
Julia.Diamond@nyulangone.org
Interventions
  • Drug: Psilocybin — One-time dose of psilocybin 25 mg, oral, in capsule form.
  • Drug: Placebo — One-time dose of placebo (25 mg of inert filler), oral, in capsule form.
Study Locations (1 sites)
NYU Langone Health, New York, New York 10016 United States
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 65 years * Able to provide voluntary signed and dated informed consent. * Females of childbearing potential (FOCBP) must agree to practice an effective means of birth control throughout the duration of the trial * Males who have FOCBPs as partners must agree to practice an effective means of birth control throughout the duration of the trial * State willingness to comply and be available for all study requirements, including psychological, cognitive, imaging and procedural evaluations for the duration of the study * Meet DSM-5 criteria for major depressive disorder (MDD) * Screening Dimensional Anhedonia Rating Scale (DARS) total score of \< 28.5 points * Have an identified support person * Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator. Exclusion Criteria: * Inability to speak and understand English sufficiently to complete informed consent and study procedures. * Inability to provide informed consent. * Women who are pregnant or who intend to become pregnant or nurse during the study duration. * Prior exposure to classic psychedelics (i.e., psilocybin, LSD, ayahuasca, and/or mescaline) within the past 1 year. * Current or previous psychiatric conditions that meet DSM-5 criteria for psychotic disorders (i.e., schizophrenia, schizoaffective disorder, MDD with psychosis), bipolar 1 or 2 disorder, or current diagnosis of active substance use disorder. * Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS assessment (severity score \> 3) at the Screening visit, confirmed by the Investigator. * Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator. * Immediate family history (i.e., parents, full siblings, or half siblings) with known or suspected psychotic disorder. * Presence of medical conditions that may confound results of imaging study or that are contraindications to or psilocybin exposure (i.e., neurological, renal, hypertension, metabolic or cardiovascular disease or pregnancy); * Presence of contraindications to MRI scanning (implantable devices, bone hardware, various IUD). * Participants who received electroconvulsive therapy (ECT), trans magnetic cranial stimulation (TMS), and/or ketamine in the past 90 days. * Has any other physical or psychological symptom, medication, or other relevant finding prior to randomization that, based on the clinical judgment of trial personnel, would make a participant unsuitable for the trial. * Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements.
Conditions Post-stroke Depression, Subthreshold Dep...
Phase NA
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The overall objective of the project is to determine the effectiveness of tele-delivered behavioral activation (BA) by trained lay counselors (Tele-BA-S) to prevent Post-stroke depression (PSD) in low-income, older stroke survivors with subthreshold depression (SD).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Tele-delivered Behavioral Activation by lay counselors after Stroke (Tele-BA-S) — The Tele-BA-S intervention will comprise 5 weekly video-conferenced BA sessions delivered by trained lay counselors, homework, and 2 monthly follow-up booster calls. Participants will receive the standard hospital discharge post-stroke educational packet and a scheduled follow-up appointment with a stroke practitioner to evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.
  • Behavioral: Treatment as Usual — Participants will receive the standard hospital discharge post-stroke educational packet and a scheduled follow-up appointment with a stroke practitioner to evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.

Primary Outcomes

  • Post-Stroke Depression as Assessed by Score on the Hamilton Depression Rating Scale (HDRS) 24-item (baseline, 2 months, 4 months, 6 months, 9 months)
  • Subthreshold Depression (Depressive Symptoms) as Assessed by the Patient Health Questionnaire (PHQ-9) (baseline, 1 month, 2 months, 4 months, 6 months, 9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-10
Completion: 2029-11-01
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Jennifer Beauchamp, PhD, RN (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Jennifer Beauchamp, PhD, RN
713-500-2114
Jennifer.e.Beauchamp@uth.tmc.edu
Jennifer Beauchamp, PhD, RN
713-500-2114
Jennifer.e.Beauchamp@uth.tmc.edu
The University of Texas Health Science Center at Houston
Interventions
  • Behavioral: Tele-delivered Behavioral Activation by lay counselors after Stroke (Tele-BA-S) — The Tele-BA-S intervention will comprise 5 weekly video-conferenced BA sessions delivered by trained lay counselors, homework, and 2 monthly follow-up booster calls. Participants will receive the standard hospital discharge post-stroke educational packet and a scheduled follow-up appointment with a stroke practitioner to evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.
  • Behavioral: Treatment as Usual — Participants will receive the standard hospital discharge post-stroke educational packet and a scheduled follow-up appointment with a stroke practitioner to evaluate patients at 7-14 days and 3 months ±14 days, according to current standard of care. They will be seen over video or in-person, according to their preference and capabilities.
Study Locations (1 sites)
The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Enrollment within 3-months +2 weeks of a first-time ischemic or hemorrhagic stroke * 24-item HDRS score \< 15 indicating subthreshold depression defined as the absence of depressive symptoms or presence of mild symptoms of depression * Single person income less than or equal to $45,000 * Residing in a community residence * Ability to speak and read in English or Spanish * Mini-MoCA score \> or equal to 11 Exclusion Criteria: * Stroke event unrelated to vascular risk factors (e.g., drug use) or transient ischemic attack * 24-item HDRS score \> or equal to 15 indicating moderate to severe depression * Actively participating in psychotherapy * high suicide risk or severe psychiatric illness (e.g., bipolar disorder and active psychosis) and/or actively taking antipsychotics * Diagnosed dementia and/or currently taking cognitive enhancers, amyloid-targeting medications, or orexin receptor antagonists * Patient Health Questionnaire 9 score \> or equal to 10 and/or answers positive to Q9 * Diagnosed aphasia and/or severe cognitive impairments * high-risk alcohol or drug misuse * receiving medications for mood disorders and a change in dose or type within the last 4 weeks
Conditions Adolescent, Bipolar Depression, tDCS, Pr...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. Participants will be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care. Biological data, including neuroimaging, blood biomarkers, voice and facial features, Photoplethysmography (PPG), Electroencephalography (EEG), and behavioral data, will be collected to explore potential predictors of treatment response.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active HD-tDCS — HD-tDCS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
  • Drug: Antipsychotics, mood stabilizers, etc. — During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
  • Device: Sham HD-tDCS — Sham HD-tDCS is administered using the same electrode configuration as the active HD-tDCS condition. During each session, the device ramps up current briefly (typically 30 seconds) to mimic the initial sensation of stimulation, then remains off for the remainder of the 20-minute session. This method produces the same tactile perception as active stimulation without delivering a therapeutic dose of current.

Primary Outcomes

  • Change from baseline in depressive symptoms assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at Week 2. (Baseline and after 2 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-16
Completion: 2027-12-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jiangsu Province Nanjing Brain Hospital
Principal Investigators:
  • Fei Wang (STUDY_CHAIR) - the Affiliated Nanjing Brain Hospital, Nanjing Medical University
Contact Information
Study Contact:
Lifei Wang
86-13390599200
lifeiwang@stu.njmu.edu.cn
Jia Duan
86-025-83295957
jia_duan@yeah.net
Fei Wang
86-025-83295957
fei.wang@yale.edu
Affiliated Nanjing Brain Hospital, Nanjing Medical University
Interventions
  • Device: Active HD-tDCS — HD-tDCS is a non-invasive neuromodulation therapy which has been recognized as a helpful treatment for depression. During each HD-tDCS treatment, the electrode field is generated by a 4\*1 ring montage which is placed over the scalp on the brain region of interest with an electrical current induced to modulate brain activity.
  • Drug: Antipsychotics, mood stabilizers, etc. — During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
  • Device: Sham HD-tDCS — Sham HD-tDCS is administered using the same electrode configuration as the active HD-tDCS condition. During each session, the device ramps up current briefly (typically 30 seconds) to mimic the initial sensation of stimulation, then remains off for the remainder of the 20-minute session. This method produces the same tactile perception as active stimulation without delivering a therapeutic dose of current.
Study Locations (1 sites)
Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: * Between 12 and 18 years of age; * Participants fulfill the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnostic criteria for bipolar disorder (BD). Participants are assessed by the Structured Clinical Interview for DSM-IV for Axis I Disorders (SCID-I, patients' age ≥18 years old), or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K- SADS-PL, patients' age\< 18 years old); * A current moderate or severe depressive episode defined by HAMD≥17 and Young Mania Rating Scale (YMRS) \<12; * Participants receive a stable psychotropic medication regimen prior to randomization to the trial and are willing to remain on the stable regimen during the HD-tDCS treatment phase; * Participants and 1 or 2 parents (patients' age\< 18 years old) provide informed consent after the detailed description of the study. Exclusion Criteria: * Prior rTMS or tDCS or electroconvulsive therapy (ECT) treatment or standard psychological therapy within 6 months prior to screening; * Comorbidity of other DSM-IV axis I disorders or personality disorders; * Judged clinically to be at serious suicidal risk; * Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities; * Unstable medical conditions, e.g., severe asthma; * Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases; * Mental retardation or autism spectrum disorder; * Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants); * Contraindications to tDCS (e.g., metal in head, history of seizure, EEG test suggesting high risk of seizure, known brain lesion); * Current drug/alcohol abuse or dependence; * Pregnant or lactating female.

Sleep TMS for Depression

NCT06824415
Recruiting
Conditions Major Depression, Sleep
Phase NA
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to establish the feasibility, tolerability, and preliminary efficacy of sleep-state transcranial magnetic stimulation (TMS) for enhancing plasticity in depression treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Double

Interventions / Regimen

  • Device: TMS — Transcranial magnetic stimulation (TMS) applies magnetic pulses to stimulate nerve cells in the brain.

Primary Outcomes

  • Change in Baseline TMS-EEG after iTBS (Baseline, end of iTBS (3 minutes))
  • Change in Baseline TMS-EEG after NREM Sleep (Baseline, end of sleep stage (3 hours))
  • Change in N-back Accuracy Performance (Baseline, end of sleep stage (3 hours))
  • Change in N-back Reaction Time Performance (Baseline, end of sleep stage (3 hours))
  • Change in MSIT Accuracy Performance (Baseline, end of sleep stage (3 hours))
  • Change in MSIT Reaction Time Performance (Baseline, end of sleep stage (3 hours))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2028-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Collaborators: National Center for Advancing Translational Sciences (NCATS), National Institute of Mental Health (NIMH)
Principal Investigators:
  • Umair Hassan, PhD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Hansong Lee, MS
408-909-2203
kellerlab@stanford.edu
Hansong Lee, MS
408-909-2203
kellerlab@stanford.edu
Stanford University
Interventions
  • Device: TMS — Transcranial magnetic stimulation (TMS) applies magnetic pulses to stimulate nerve cells in the brain.
Study Locations (1 sites)
Stanford University, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Adults ages 18-65 years * Current Major Depressive Disorder (MDD) diagnosis * Failed ≥1 antidepressant medication * Moderate-to-severe depression * Stable antidepressant medication dose for ≥ 6 weeks prior to enrollment * Healthy control participants are adults ages 18-65 years without current MDD symptoms, not taking antidepressant or antipsychotic medications, and without major psychiatric, neurological, substance use, medical conditions affecting brain function, or TMS/MRI contraindications. Exclusion Criteria: * Intellectual disability * Significant head injury/neurological disorder * Pregnancy or postpartum * TMS/MRI contraindications * Active substance use/suicidal ideation
Conditions Interstitial Lung Disease, Precapillar P...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Fibrosing interstitial lung diseases (FILDs) encompass a group of rare diseases characterized by progressive pulmonary fibrosis leading to respiratory failure. Current treatments primarily aim to slow disease progression but remain limited, making lung transplantation the ultimate recourse. The development of pulmonary hypertension (PH) in the context of FILDs significantly worsens morbidity and mortality and drastically reduces patients' life expectancy. Conventional treatments for PH are generally ineffective in this setting. Nevertheless, some promising therapeutic agents are currently under investigation, particularly inhaled prostacyclin analogs such as treprostinil, which have demonstrated efficacy in recent clinical studies. Our study aims to explore, in a minimally invasive manner, variations in metabolites in the serum and urine of patients with PH secondary to FILDs, before and during treatment. The main objective is to better understand the systemic effect of these treatments. Furthermore, the identification of metabolomic signatures will allow us to differentiate responders from non-responders, thus providing valuable prognostic and predictive criteria. To date, some patients do not benefit from the available treatments, and better selection of responders could prevent iatrogenic effects in patients whose clinical condition is already fragile. In addition, characterizing the systemic mode of action of these treatments could pave the way for new clinical research focused on the profiles of responding patients. Finally, a thorough understanding of the efficacy of the studied therapies is essential. Indeed, effective treatment of PH in the context of FILDs could not only slow disease progression but also reduce the need for lung transplantation, a major challenge in a context of organ shortage.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Blood sampling for metabolomic profiling — Blood (veinous) will be collected under standard care conditions, in a dry red blood tube without additional gel (4 mL) to obtain serum after centrifugation for 10 minutes at 1500g, in the form of 500µL aliquots, labelled with the patient's code in the study. This sampling will be performed at baseline in both group; and after follow up completion in Group 1 (4-6 month)
  • Other: Urine sampling for metabolomic profiling — Urine collected from patient into a dry powder compact in the waiting room before or after the consultation. Preparation of two cryotubes containing at least 1 mL per sample, labelled with the patient's code in the study. In the absence of a calling point, strict aseptic conditions are not required, as the use of chemicals or antiseptic soaps can interfere with the dosages. This sampling will be performed in Group 1 and 2 at baseline; and in Group 1 at 2-month and after completion of follow-up time (4-6 month).

Primary Outcomes

  • Comparison of urinary metabolite concentrations before and after initiation of treatment measured centrally by proton nuclear magnetic resonance spectroscopy (¹H-NMR). (Outcome is measured when all patients will have their 4-6 months follow-up completed.)
  • Comparison of blood metabolite concentrations before and after initiation of treatment measured centrally by proton nuclear magnetic resonance spectroscopy (¹H-NMR). (Outcome is measured when all patients will have their 4-6 months follow-up completed.)
  • Comparative prognosis analysis within sub-groups (Outcome is measured when all patients will have their 4-6 months follow-up completed.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-02-16
Completion: 2029-08-16
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospices Civils de Lyon
Contact Information
Study Contact:
Ségolène TURQUIER
04 72 35 73 32
segolene.turquier@chu-lyon.fr
David LAVILLE
04 27 85 51 39
david.laville@etu.univ-lyon1.fr
Ségolène TURQUIER
04 72 35 73 32
segolene.turquier@chu-lyon.fr
Hôpital Cardiologique et Pneumologique Louis Pradel
Interventions
  • Other: Blood sampling for metabolomic profiling — Blood (veinous) will be collected under standard care conditions, in a dry red blood tube without additional gel (4 mL) to obtain serum after centrifugation for 10 minutes at 1500g, in the form of 500µL aliquots, labelled with the patient's code in the study. This sampling will be performed at baseline in both group; and after follow up completion in Group 1 (4-6 month)
  • Other: Urine sampling for metabolomic profiling — Urine collected from patient into a dry powder compact in the waiting room before or after the consultation. Preparation of two cryotubes containing at least 1 mL per sample, labelled with the patient's code in the study. In the absence of a calling point, strict aseptic conditions are not required, as the use of chemicals or antiseptic soaps can interfere with the dosages. This sampling will be performed in Group 1 and 2 at baseline; and in Group 1 at 2-month and after completion of follow-up time (4-6 month).
Study Locations (1 sites)
Hôpital Cardiologique et Pneumologique Louis Pradel, Bron, Rhone 69500 France
Eligibility Criteria
Inclusion Criteria: * Patients suffering from progressive interstitial lung disease (ILD) and especially lung fibrosis * Suspicion of precapillar pulmonary hypertension (group 3 PH / ILD-PH) * Patients undergoing cardiac catheterisation for haemodynamic confirmation * Patient who has given informed consent Exclusion Criteria: * Patients suffering from other forms of PH (i.e. PAH, CTEPH, heart failure, multifactorial
Conditions Hemodynamics
Phase NA
Enrollment 68
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

In this clinical trial, the authors will compare two tourniquet deflation techniques and their clinical implications on hemodynamics and acid base parameters in hypertensive orthopedic patients undergoing upper limb surgeries under general anesthesia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Triple

Interventions / Regimen

  • Device: Tourniquet deflation — Tourniquet deflation technique

Primary Outcomes

  • Mean Arterial Pressure (5 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-13
Completion: 2026-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 68 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kasr El Aini Hospital
Contact Information
Study Contact:
Khaled Sarhan, MD
+201020067816
khaled.sarhan@kasralainy.edu.eg
Khaled Sarhan, MD
+201020067816
khaled.sarhan@kasralainy.edu.eg
Cairo university hospitals
Interventions
  • Device: Tourniquet deflation — Tourniquet deflation technique
Study Locations (1 sites)
Cairo university hospitals, Cairo, Egypt
Eligibility Criteria
Inclusion Criteria: * Hypertensive patients (controlled on medical treatment more than three months) * Patients scheduled for upper limb orthopedic surgeries using a tourniquet for at least 30 min. * BMI from 18.5 to 29.9 Exclusion Criteria: * Patient refusal * ASA physical status \> II * Multiple orthopedic surgeries * Emergency surgeries * Patient with relative contraindications for tourniquet use